Vertaile menetelmiä

	Sinonasal Outcome Test-22	Breathlessness, Cough, and Sputum Scale
Tieteenala	Keuhkosairausoppi	Keuhkosairausoppi
Menetelmäperhe	Process / pipeline	Process / pipeline
Syntyvuosi	2009	2007
Kehittäjä	Claire Hopkins, King's College London	Multiple international authors (cardiopulmonary collaboration)
Tyyppi	Self-report questionnaire	Self-report symptom scale
Alkuperäislähde	Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009). Psychometric validity of the 22-item Sinonasal Outcome Test. Clinical Otolaryngology, 34(5), 447-454.	Rohrmann, S., Anker, S. D., Coats, A. J., Hildebrandt, P., & Köhler, F. (2007). Prognostic relevance of respiratory symptoms in patients with systolic left ventricular dysfunction. American Heart Journal, 153(1), 42-50.
Rinnakkaisnimet	SNOT-22, SNOT	BCS, Breathlessness Cough Sputum
Liittyvät	5	5
Tiivistelmä	The SNOT-22 is a 22-item disease-specific quality-of-life questionnaire designed to assess sino-nasal symptoms and their functional impact on patients with chronic rhinosinusitis, nasal polyposis, and allied conditions. Developed by Hopkins and colleagues at King's College London in 2009, it has become the most widely used instrument for measuring sino-nasal disease burden in clinical trials and rhinological practice. The SNOT-22 provides rapid, patient-centered assessment of both nasal-specific symptoms (congestion, drainage, sneezing) and general health impacts (sleep, headache, concentration).	The BCS is a brief, symptom-focused assessment tool measuring the frequency and severity of three cardinal respiratory symptoms: breathlessness (dyspnea), cough, and sputum production. Developed in cardiopulmonary research as a pragmatic measure of disease burden in chronic heart failure and chronic obstructive pulmonary disease, the BCS provides rapid, patient-centered tracking of respiratory symptom trajectories. Unlike comprehensive quality-of-life questionnaires, the BCS concentrates solely on symptom phenotype, making it ideal for routine monitoring and longitudinal disease surveillance in busy clinical settings.